Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of the VETA trial is to verify the potential beneficial effects of the
combination of micronutrients namely Vitamin D3 and K2 in combination with oral
antihyperglycemic Empagliflozin in Diabetes Mellitus